Propanc Biopharma files fourth patent application with IP Australia

Propanc Biopharma (PPCB) announced the filing of its fourth new provisional patent application in the past two months with IP Australia. This latest application focuses on formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen. “Filing four provisional patent applications in such a short timeframe underscores our relentless drive to protect and expand our groundbreaking proenzyme technology,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “As these applications advance to national phase entry across major global markets, we expect to more than double our IP portfolio – from approximately 90 to over 200 patents – covering compositions, formulations, treatment methods, and new therapeutic indications.”.